GlassScriptPhysician profile
Manuel W Cruz
NPI 1700833902
$1,680.74
in general payments reported to CMS, 2019-2025
17 companies · $321 in 2025
The $321 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $422 · 2020: $199 · 2021: $261 · 2022: $195 · 2023: $92.53 · 2024: $190 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $649.09 | 2019-2025 | Ensite, Gallant, Aveir |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $496.77 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $142.36 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $77.95 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $56.55 | 2025 | Apollo Esg System |
| Pfizer INC. | $44.20 | 2019-2021 | |
| Novo Nordisk INC | $43.99 | 2023 | Rybelsus, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $31.44 | 2024 | Camzyos, Eliquis |
| Myocardial Solutions, INC. | $28.93 | 2021 | |
| Esperion Therapeutics, INC. | $26.22 | 2021 | |
| Surmodics, INC. | $16.59 | 2022 | |
| Elutia, INC. | $14.96 | 2019 | |
| Astellas Pharma US INC | $14.67 | 2019 | |
| Baxter Healthcare | $14.07 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Philips North America LLC | $13.90 | 2025 | Ecc Solutions |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Althera Pharmaceuticals LLC | $9.05 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,328.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.